Aytu BioPharma, Inc.
2.1800+0.02 (+0.93%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · AYTU · USD
Key Stats
Market Cap
22.21MP/E (TTM)
-Basic EPS (TTM)
-2.26Dividend Yield
0%Recent Filings
8-K
AR101 agreement terminated
Aytu BioPharma terminated its AR101 asset purchase agreement with Rumpus entities and EnzCo on August 5, 2025, transferring all rights to EnzCo for mutual consideration and releases. This ends all obligations under the April 21, 2021 deal, following the program's clinical suspension. No penalties apply. Clean break achieved.
8-K
Aytu extends Eclipse loan to 2029
Aytu BioPharma extended its loan and security agreement with Eclipse Business Capital, pushing the term loan and revolving facility maturities to June 12, 2029, while boosting the term loan principal to $13.0 million from $11.1 million and adding a $1.5 million incremental advance to the revolver at SOFR plus 5.50%, with monthly repayments starting August 1, 2025. This restructuring enhances working capital flexibility amid preparations for the Q4 2025 launch of EXXUA, a first-in-class antidepressant targeting the $22 billion U.S. MDD market. Lenders raised concentration limits to 25% for independent pharmacy distributors. Yet, the added debt signals reliance on external funding for growth.
8-K
Updated EXXUA investor deck
Aytu BioPharma released an updated investor presentation on June 17, 2025, highlighting the EXXUA™ (gepirone) extended-release tablets opportunity for upcoming meetings. The deck, attached as Exhibit 99.1, details strategic insights but carries no financial figures or forward guidance. Investors get a fresh look at gepirone's potential. Yet, it's not filed under securities laws.
8-K
Aytu closes $16.6M offering
Aytu BioPharma closed an upsized public offering of 2,806,688 common shares and 8,233,332 prefunded warrants at $1.50 each, raising $16.6 million in gross proceeds before expenses. Funds will support working capital and exclusive commercialization of EXXUA, its FDA-approved first-in-class antidepressant for major depressive disorder, targeting the $22 billion U.S. market with a Q4 2025 launch. EXXUA showed efficacy in over 5,000 patients and avoids sexual side effects. Yet risks like QT prolongation loom.
8-K
Aytu prices $14.4M stock offering
Aytu BioPharma priced an upsized public offering of 9.6 million shares—or prefunded warrants—at $1.50 each, expecting $14.4 million in gross proceeds before fees. The deal, led by Nantahala Capital and others, closes around June 9, 2025, funding general purposes and a transaction to exclusively commercialize EXXUA for depression. Yet market volatility could delay closure.
IPO
Website
Employees
Sector
Industry
AMRX
Amneal Pharmaceuticals, Inc.
10.43+0.14
ANIP
ANI Pharmaceuticals, Inc.
92.23-1.06
AVDL
Avadel Pharmaceuticals plc
18.90+0.31
AYRWF
AYR WELLNESS INC.
0.02+0.00
ELTP
Elite Pharmaceuticals, Inc.
0.60-0.01
NXEN
Nexien BioPharma, Inc.
0.01+0.00
RGC
Regencell Bioscience Holdings L
16.61-0.67
TEVA
Teva Pharmaceutical Industries
20.23+0.45
TLPH
Talphera, Inc.
1.23-0.07
VTRS
Viatris Inc.
10.27-0.02